23.36
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
-
|
- | - | 0.439 | 8.897 |
Research and Development |
38.35%
34.66
|
25.05 | - | - | - |
Operating Income/Loss |
29.29%
-45.12
|
-34.90 | -29.02 | -35.84 | -13.82 |
Nonoperating Income/Loss |
1.13%
11.26
|
11.39 | 8.806 | 7.783 | 7.863 |
Income/Loss From Continuing Operations Before Tax |
44.03%
-33.86
|
-23.51 | -20.22 | -28.06 | -5.959 |
Income/Loss From Continuing Operations After Tax |
44.03%
-33.86
|
-23.51 | -20.22 | -28.06 | -5.959 |
|
44.03%
-33.86
|
-23.51 | -20.22 | -28.06 | -5.959 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
0.18%
61.90
|
61.79 | 1.0345 | 54.63 | 54.45 |
Diluted Average Shares |
0.18%
61.90
|
61.79 | 1.0345 | 54.63 | 54.45 |
Basic Earnings Per Share |
44.74%
-0.55
|
-0.38 | -0.35 | -0.51 | -0.11 |
Diluted Earnings Per Share |
44.74%
-0.55
|
-0.38 | -0.35 | -0.51 | -0.11 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):